UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials
Dallas, Texas, 75390-8802, United States
NCT Number: NCT00616239
This study will enroll 20 adult Hispanic women. Participants will apply 4% hydroquinone cream twice daily to affected areas on the face for 14 weeks and half the face will be peeled with 20-30% salicylic acid every two weeks for a total of 4 peels. The first two peels will be 20% salicylic acid and the second two peels will be with 30% salicylic acid. The purpose of the study will be to evaluate the safety and efficacy of salicylic acid combined with 4% hydroquinone versus 4% hydroquinone alone.
Looking for future studies?
Notify Me18 year–65 year
Female
Interventional
Phase 4
Dallas, Texas, 75390-8802, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
Other names: Chemical Peels
Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
Other names: Chemical Peels
Time frame: 14 weeks
Improvement of melasma on the peel side using mexameter reading
University of Texas Southwestern Medical Center
Other
The Efficacy of Salicylic Acid Peels Combined With 4% Hydroquinone Cream Versus 4% Hydroquinone Cream Alone in the Treatment of Hispanic Women With Moderate to Severe Melasma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07727954
Hyperpigmentation, Melanosis
Tijuana, Estado de Baja California, Mexico
View Trial DetailsNCT07676994
Hyperpigmentation, Melanosis
Lahore, Pakistan
View Trial DetailsNCT07644871
Dark Spots, Hyperpigmentation
Irving, Texas, United States
View Trial DetailsNCT03877445
Hyperpigmentation, Melanosis
Nice, France
View Trial Details